Stock Analysis
uniQure N.V. (QURE) Stock Analysis
uniQure N.V. (QURE) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
uniQure N.V. (QURE) currently has an AIQ Score of 39/100, indicating a bearish setup. Quality is the strongest factor at 42/100. Risk is the weakest current factor at 31/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
QURE at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $23.81 |
| AIQ Score | 39/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Neutral |
| Market Cap | $1.66B |
| P/E Ratio (TTM) | -6.73 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.88 |
| Revenue (Q3 FY2026) | $5.2M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.68 |
| Volume | 1.39M |
| 52-week range | $8.73-$51.72 |
| RSI 14 | 45.74 |
| 50-Day SMA | $29.50 |
| 200-Day SMA | $29.64 |
| Analyst Price Target | $50.17 |
| Next Earnings | Mar 1, 2027 |
QUREuniQure N.V.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum41
- Value38
- Quality42
- Risk resilience31
- Sentiment—
QURE Stock Analysis Summary
uniQure N.V. (QURE) currently has an AIQ Score of 39/100, indicating a bearish setup. Quality is the strongest factor at 42/100. Risk resilience is the weakest current factor at 31/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, QURE has AIQ Score of 39/100 with Quality base of 42/100 and fading Risk resilience at 31/100. Wait for component alignment before adding exposure.
Healthcare · -3.33% stock move · QURE classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is QURE Bullish or Bearish Right Now?
QURE currently has a bearish overall setup. Quality is the strongest factor at 42/100, while Risk Resilience is weakest at 31/100. The current evidence suggests a bearish setup.
- - Analyst target implies +110.70% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (22 vs 17).
- - Value is the current constraint at 38/100.
- - Momentum is weak at 41/100.
- - Risk Resilience is weak at 31/100.
- - Price is -19.68% below its 200-day SMA.
Current Consensus
QURE's Technical Analysis Consensus is currently Neutral, with 22 buy, 7 neutral, and 17 sell votes. QURE's 14-day RSI is 45.74, which places the stock in a neutral momentum range. QURE's beta is 0.68, indicating lower market sensitivity than the broad market.
What Changed in QURE?
The largest recent change in QURE is Momentum moving down by 4.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the QURE Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
QURE Decision Framework
Public evidence layers, setup checks, and risk context for uniQure N.V..
uniQure N.V. (QURE) Stock Analysis
uniQure N.V. has an AIQ Score of 39/100 in a Bearish regime. Quality is strongest at 42/100. Beta is 0.68, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | QURE is in a Bearish AIQ regime with score 39/100. |
| Signal Conflict | The primary conflict is that quality leads at 42/100 while risk lags at 31/100. |
| Factor Evidence | Momentum 41/100 · Value 38/100 · Quality 42/100 · Risk 31/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 42/100.
Momentum is 41/100 and RSI (14) is 45.7.
QURE is in a Bearish regime at 39/100.
Risk factor is 31/100 with beta 0.68 and annual volatility 132.25%.
Current conflict: quality leads at 42/100 while risk lags at 31/100.
QURE Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
QURE Fundamentals
QURE valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
QURE Technical Analysis
QURE technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
QURE Stock Catalysts
Track QURE earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
QURE Dividend Analysis
QURE dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
QURE Financial Data
QURE revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
QURE Risk Analysis
QURE volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
QURE Stock News
QURE stock news, market tone, recent headlines, and catalyst context.
QURE vs Biotechnology Peers
Current peer cohort: QURE · RAPP · RCUS · REPL · RLAY. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| QURE Current stock | 39/100 | 38/100 | 41/100 | 31/100 | 0.39 | 132.25% | Current |
| RAPP Rapport Therapeutics, Inc. Common Stock | 43/100 | 42/100 | 33/100 | 39/100 | 0.35 | 62.34% | QURE vs RAPP |
| RCUS Arcus Biosciences, Inc. | 39/100 | 43/100 | 34/100 | 42/100 | 0.05 | 62.65% | QURE vs RCUS |
| REPL Replimune Group, Inc. | 60/100 | — | 97/100 | 26/100 | 1.3 | 187.93% | QURE vs REPL |
| RLAY Relay Therapeutics, Inc. | 56/100 | 37/100 | 76/100 | 52/100 | 1.84 | 65.80% | QURE vs RLAY |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for QURE: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching QURE
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for QURE
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
QURE Stock FAQ
What is QURE stock price today?
uniQure N.V.'s current stock price is $23.81. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is QURE bullish or bearish right now?
QURE's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is QURE's market cap?
QURE's market cap is $1.66B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is QURE's current P/E ratio?
QURE's current P/E ratio is -6.73 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is QURE's RSI?
QURE's 14-day RSI is 45.74 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is QURE above its 50-day and 200-day moving averages?
QURE is -19.29% from its 50-day SMA and -19.68% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is QURE's next earnings date?
QURE's next earnings date is currently listed as Mar 1, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does QURE pay a dividend?
QURE's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.